Dateline City:
KENILWORTH, N.J.
KEYTRUDA Monotherapy Achieved Overall Response Rate of 22.2 Percent in Previously-Treated Patients
Results from KEYNOTE-028 Presented at 2015 European Cancer Congress
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced the first-time presentation of findings investigating
the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1
therapy, as a monotherapy in patients with advanced unresectable
nasopharyngeal carcinoma (NPC) a type of head and neck cancer whose
tumors express PD-L1 (1% of cells in tumor nests or PD-L1+ bands in
stroma).
Language:
English
Contact:
MerckMedia:Pamela Eisele, (267) 305-3558An Phan, (908) 255-6325orInvestor:Justin Holko, (908) 740-1879Teri Loxam, (908) 740-1986
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more